Compare ELOG & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELOG | MBAI |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | China | Israel |
| Employees | N/A | 85 |
| Industry | Integrated Freight & Logistics | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4M | 12.0M |
| IPO Year | N/A | N/A |
| Metric | ELOG | MBAI |
|---|---|---|
| Price | $0.92 | $1.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 36.0K | ★ 46.8K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $1.31 |
| 52 Week High | $3.07 | $3.92 |
| Indicator | ELOG | MBAI |
|---|---|---|
| Relative Strength Index (RSI) | 37.11 | 42.42 |
| Support Level | $0.84 | $1.44 |
| Resistance Level | $1.19 | $1.83 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 0.75 | 19.45 |
Eastern International Ltd is a holding company. The company operates through its subsidiary engaged in domestic and cross-border professional logistic services including project logistics and general logistics for company clients. Its project logistic services include Construction project logistics and special cargo logistics for large or precision equipment and General logistic services refer to the transportation, warehousing, loading and unloading, and distribution of ordinary products. Its segments are Transportation services and Warehouse subleasing services. The group generates the majority of its revenue from Transportation services.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.